Low Endotoxin Gelatin Market Report 2026

Low Endotoxin Gelatin Market Overview

• Low Endotoxin Gelatin market size has reached to $1.84 billion in 2025 • Expected to grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 6.7% • Growth Driver: The Growing Demand For Regenerative Medicine Is Fueling The Growth Of The Market Due To Its Reliance On Safe, Biocompatible Scaffolds • Market Trend: Advancement In Endotoxin-Controlled Excipients Enhancing Pharmaceutical Safety • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Low Endotoxin Gelatin Market?

Low endotoxin gelatin is a highly purified gelatin with minimal endotoxin levels, reducing the risk of adverse immune responses. It is specifically designed for safe use in sensitive biological applications such as drug delivery, tissue engineering, and regenerative medicine. Its high purity ensures compatibility with delicate cell systems and biomedical environments. The main types of low endotoxin gelatin are type A (acid-processed gelatin) and type B (alkaline-processed gelatin). Type A gelatin, derived from porcine skin via acid treatment, offers quick solubility and high purity, making it ideal for fast-setting pharmaceutical and medical applications. The product type is such as porcine gelatin, bovine gelatin, fish gelatin, and others with various formulations, including powder, granules, liquid, sheet, and others. It is applicable in several applications, such as drug delivery systems, tissue engineering, cell culture, stabilizing agents, and thickening agents, and is used by various end-users, including pharmaceuticals, biotechnology, food and beverage, cosmetics, and research laboratories.

What Is The Low Endotoxin Gelatin Market Growth Forecast?

The low endotoxin gelatin market size is expected to see strong growth in the next few years. It will grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to surge in regenerative medicine applications, increased investment in biopharmaceutical manufacturing, rising demand for injectable gelatin products, development of novel biotech-grade gelatin formulations, adoption of sustainable production methods. Major trends in the forecast period include growing demand for biocompatible materials, expansion of regenerative medicine applications, increasing use in drug delivery systems, rising focus on cell culture safety and purity, adoption of advanced formulation techniques.

Global Low Endotoxin Gelatin Market Segmentation

1) By Processing Method: Type A (Acid Process Gelatin), Type B (Alkaline Process Gelatin) 2) By Product Type: Porcine Gelatin, Bovine Gelatin, Fish Gelatin, Other Product Types 3) By Formulation: Powder, Granules, Liquid, Sheet, Other Formulations 4) By Application: Drug Delivery Systems, Tissue Engineering, Cell Culture, Stabilizing Agents, Biomedical Scaffolding And Encapsulation Uses 5) By End-User: Pharmaceuticals, Biotechnology, Medical Device Manufacturers, Regenerative Medicine Developers, Research Laboratories Subsegments: 1) By Type A (Acid Process Gelatin): Porcine Skin Gelatin, Fast Setting Gelatin, Low Bloom Gelatin, Pharmaceutical Grade Type A, Biotech Application Grade 2) By Type B (Alkaline Process Gelatin): Bovine Hide Gelatin, High Bloom Gelatin, Slow Dissolving Gelatin, Injectable Grade Type B, Regenerative Medicine Grade

What Is The Driver Of The Low Endotoxin Gelatin Market?

The growing demand for regenerative medicine is expected to propel the growth of the low endotoxin gelatin market going forward. Regenerative medicine refers to therapies that repair, replace, or regenerate human cells, tissues, or organs to restore normal function. This regenerative medicine demand is increasing due to rising chronic diseases, as more patients require advanced therapies that can regenerate damaged tissues and improve long-term outcomes. Low-endotoxin gelatin aids regenerative medicine by offering a safe, biocompatible scaffold that promotes cell growth and tissue regeneration with minimal immune reaction. Its high purity makes it ideal for sensitive cell therapies and tissue engineering. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, at the end of quarter 1, 2023, there were 247 gene therapies in Phase II. This figure increased by 5%, reaching 260 by the end of quarter 2. Therefore, the growing demand for regenerative medicine is driving the growth of the low endotoxin gelatin industry.

Key Players In The Global Low Endotoxin Gelatin Market

Major companies operating in the low endotoxin gelatin market are Nagase & Co. Ltd., Darling Ingredients, GELITA AG, PB Leiner, Nippi Inc., Nitta Gelatin Inc., Weishardt Group, Sterling Biotech Limited, Narmada Gelatines Ltd., Great Lakes Gelatin Company, Junca Gelatines SL, Trobas Gelatine BV, Lapi Gelatine S.p.A., Ewald-Gelatine GmbH, India Gelatine & Chemicals Ltd., Reinert Gruppe Ingredients GmbH, Jilin Tianzheng Biotechnology Co. Ltd., Yasin gelatin, Rousselot Biomedical, Advanced BioMatrix Inc., Gelomics Pty Ltd., BDF Natural Ingredients

Global Low Endotoxin Gelatin Market Trends and Insights

Major companies operating in the low endotoxin gelatin market are focusing on developing advanced products such as endotoxin-controlled excipients to enhance the safety and efficacy of pharmaceutical formulations. Endotoxin-controlled excipients are highly refined ingredients designed to limit endotoxin presence in pharmaceutical formulations. They support the safety and reliability of sensitive products such as injectables, biologics, and cell-based therapies. For instance, in January 2025, GELITA, a Germany-based manufacturer of gelatin and collagen peptides, launched VACCIPRO and MEDELLAPRO. These excipients are highly purified, medical-grade gelatins and collagen peptides designed for advanced bioscience applications such as vaccine stabilization, medical devices, and 3D bioprinting, meeting stringent endotoxin control requirements to ensure product safety and patient well-being in pharmaceutical and healthcare settings.

What Are Latest Mergers And Acquisitions In The Low Endotoxin Gelatin Market?

In March 2024, BIO INX, a Belgium-based material developer for 3D bioprinting, partnered with Rousselot to advance 3D bioprinting with high-quality, standardized gelatin-based biomaterials. The partnership aims to accelerate clinical and research adoption of 3D bioprinting by developing and distributing biomedical-grade bioinks using Rousselot’s X-Pure gelatin. Rousselot Inc. is a Netherlands-based producer of lower-endotoxin gelatine.

Regional Outlook

North America was the largest region in the low endotoxin gelatin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Low Endotoxin Gelatin Market?

The low endotoxin gelatin market consists of sales of bovine bone-low-endotoxin gelatin, fish skin-low-endotoxin gelatin, and recombinant gelatin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.